Lexeo Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
LXEO$3.06-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(In thousands, except share amounts)
| Convertible · Additional · Other · Total | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Common Stock · Treasury · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||||||||||
| Shares · Amount · Shares · Amount · Stock · Capital · Loss · Deficit · Equity (Deficit) | |||||||||||||||||
| Balances at December 31, 2022 | 143,653,545 | $185,033 | 1,607,185 | $ | - | $ | - | $2,492 | $ | - | $(115,446) | $(112,954) | |||||
| Exercise of stock options | - | - | 11,916 | - | - | 51 | - | - | 51 | ||||||||
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase | - | - | 19,442 | - | - | 87 | - | - | 87 | ||||||||
| Conversion of SAFE Note into common stock in connection with initial public offering, net of issuance costs of $113 | - | - | 411,815 | - | - | 4,417 | - | - | 4,417 | ||||||||
| Issuance of common stock upon initial public offering and subsequent partial exercise of underwriters' option to purchase additional shares, net of underwriting discounts, commissions and offering costs of $11,285 | - | - | 10,139,656 | 1 | - | 100,250 | - | - | 100,251 | ||||||||
| Conversion of convertible preferred stock into common stock in connection with initial public offering, net of issuance costs of $519 | (143,653,545) | (185,033) | 14,456,364 | 2 | - | 185,032 | - | - | 185,034 | ||||||||
| Stock-based compensation expense | - | - | - | - | - | 3,043 | - | - | 3,043 | ||||||||
| Net loss | - | - | - | - | - | - | - | (66,394) | (66,394) | ||||||||
| Balances at December 31, 2023 | - | $ | - | 26,646,378 | $3 | $ | - | $295,372 | $ | - | $(181,840) | $113,535 | |||||
| Exercise of stock options | - | 135,646 | - | - | 491 | - | 491 | ||||||||||
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase | - | - | 14,159 | - | - | 59 | - | - | 59 | ||||||||
| Issuance of common stock upon private placement offering, net of commissions and offering costs of $6,288 | - | - | 6,278,905 | - | - | 88,712 | - | - | 88,712 | ||||||||
| Additional issuance costs incurred for SAFE Note | - | - | - | - | - | 24 | - | - | 24 | ||||||||
| Treasury stock repurchases | - | - | (3,827) | - | (17) | - | - | - | (17) | ||||||||
| Unrealized comprehensive loss on investments | - | - | - | - | - | - | (103) | - | (103) | ||||||||
| Stock-based compensation expense | - | - | - | - | - | 12,474 | - | - | 12,474 | ||||||||
| Net loss | - | - | - | - | - | - | - | (98,333) | (98,333) | ||||||||
| Balances at December 31, 2024 | - | $ | - | 33,071,261 | $3 | $(17) | $397,132 | $(103) | $(280,173) | $116,842 | |||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.